Epilepsy Focus Neuroscience portfolio centered on antiseizure therapies with ENX-101 and validation in GAERS epilepsy models, presenting a clear preclinical niche for specialized epilepsy CROs, in vivo electrophysiology experts, and biomarker development partners.

Strong Funding Oversubscribed Series B financing secures substantial capital to advance development, enabling partnerships, scale-up manufacturing planning, and early-phase clinical operations under milestone-driven structures.

Acquisition Experience Recent acquisition of NeuroCycle Therapeutics signals a growth-through-assembly approach; explore partnerships to integrate NeuroCycle platforms, license complementary technologies, or support portfolio expansion and due diligence services.

Flexible Deals With a flexible transaction model to move assets through development, creating opportunities for licensing, co-development, or strategic collaborations tailored to pipeline milestones and risk sharing.

Regional Biotech Hub San Diego presence with a lean team fits well with local CROs, CMOs, regulatory consultants, and biotech service providers to accelerate preclinical to clinical phases and improve time-to-market for neuroscience therapies.